Rivaroxaban Versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer

In Vivo - Greece
doi 10.21873/invivo.11845
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Anticancer Research USA Inc.

Related search

Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer

Oncologist
Cancer ResearchMedicineOncology
2012English

Low Molecular-Weight Heparin Is Better Than Warfarin for Prevention of Recurrent Venous Thromboembolism in Cancer Patients

Clinical Research in Practice: The Journal of Team Hippocrates
2017English

Cost-Effectiveness Analysis of Treatment of Venous Thromboembolism With Rivaroxaban Compared With Combined Low Molecular Weight Heparin/Vitamin K Antagonist

Thrombosis Journal
Hematology
2015English

Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal Surgery

Archives of Internal Medicine
1999English

Low-Molecular-Weight-Heparin Versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in High- And Low-Risk Patients With Active Cancer: A Post Hoc Analysis of the CLOT Study

Journal of Thrombosis and Thrombolysis
Cardiovascular MedicineHematologyCardiology
2019English

Low Molecular Weight Heparin

Reactions Weekly
2014English

Low Molecular Weight Heparin

Journal of Cardiothoracic and Vascular Anesthesia
Cardiovascular MedicineAnesthesiologyPain MedicineCardiology
1992English

Low Molecular Weight Heparin

Reactions Weekly
2013English

Low Molecular Weight Heparin

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy